The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates
Open accessAbstract
Cancer immunotherapy is a promising innovative treatment for many forms of cancer, particularly melanoma. Although immunotherapy has been shown to be efficacious, patient response rates vary and, more often than not, only a small subset of the patients within a large cohort respond favourably to the treatment. This issue is particularly concerning and becomes a challenge of immunotherapy to improve the effectiveness and patient response rates. Here, we review the specific types of available immunotherapy options, their proposed mechanism(s) of action, and the reasons why the patient response to this treatment is variable. The potential favourable options to improve response rates to immunotherapy will be discussed with an emphasis on adopting a multimodal approach on the novel role that the gut microbiota may play in modulating the efficacy of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“Additionally, cancer patients that responded to immunotherapy had an increase in antitumor killer T cells and the difference in killer T cell quantity was correlated to the presence of species within the Faecalibacterium and Clostridiales phyla [13].”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 3×
“[34] demonstrated that the rate of tumor growth decreased through oral administration of the Bifidobacteria alone or in combination with anti-PD-L1 immunotherapy in mouse models of melanoma.”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“[33] demonstrated a correlation between the effectiveness of cancer immunotherapies and the composition of the gut microbiome, thereby implicating a more involved role for probiotics.”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 2×
“One advancement of overcoming resistance to immunotherapy is the use of combination immunotherapy [17] or multimodal approaches.”
BackgroundThe gut flora as a forgotten organ
O'Hara, A. M., & Shanahan, F. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400731 · Cited by 2,791
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science · doi:10.1126/science.aah5043 · Cited by 1,817
The impact of diet and lifestyle on gut microbiota and human health
Conlon, M., & Bird, A. (2014) · Nutrients · doi:10.3390/nu7010017 · Cited by 1,567
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · cited 3×
“Although this study considered the effectiveness of immune checkpoint blockage through anti-PD-1 or antiCTLA-4 [19], the results can be translated to other forms of immunotherapy that involve antigen presentation like CART therapy and cancer vaccines.”
BackgroundCurrent Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
The immune system and the gut microbiota: friends or foes?
Cerf-Bensussan, N., & Gaboriau-Routhiau, V. (2010) · Nature Reviews Immunology · doi:10.1038/nri2850 · Cited by 704
Lipman, N. S., Jackson, L. R., Trudel, L. J., & Weis-Garcia, F. (2005) · ILAR Journal · doi:10.1093/ilar.46.3.258 · Cited by 644
Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 597
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Dietary Modulation of the Human Gut Microflora Using the Prebiotics Oligofructose and Inulin
Gibson, G. R. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.7.1438s · Cited by 383
Wang, H. Y., & Wang, R.-F. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.004 · Cited by 325
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
An injectable nanoparticle generator enhances delivery of cancer therapeutics
Xu, R., Zhang, G., Mai, J., Deng, X., Segura-Ibarra, V., Wu, S., Shen, J., Liu, H., Hu, Z., Chen, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3506 · Cited by 280
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
Ventola, C. L. (2017) · PubMed · Cited by 257
Prebiotics and the Health Benefits of Fiber: Current Regulatory Status, Future Research, and Goals,
Brownawell, A. M., Caers, W., Gibson, G. R., Kendall, C. W. C., Lewis, K. D., Ringel, Y., & Slavin, J. L. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.158147 · Cited by 248
DNA methylation and breast cancer
Szyf, M., Pakneshan, P., & Rabbani, S. A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.030 · Cited by 229
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
CAR T cell therapy: inroads to response and resistance
Brown, C. E., & Mackall, C. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0119-y · Cited by 187
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Li, K., Qu, S., Chen, X., Wu, Q., & Shi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020404 · Cited by 180
Schuster, M., Nechansky, A., & Kircheis, R. (2006) · Biotechnology Journal · doi:10.1002/biot.200500044 · Cited by 179
Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G., Royce, M., McCall, L. M., Ewer, M. S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70502-3 · Cited by 170
Boleij, A., & Tjalsma, H. (2012) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/j.1469-185x.2012.00218.x · Cited by 162
Cancer immunotherapies, their safety and toxicity
Alatrash, G., Jakher, H., Stafford, P., & Mittendorf, E. A. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.795944 · Cited by 160
Li, Z., Dong, P., Ren, M., Song, Y., Qian, X., Yang, Y., Li, S., Zhang, X., & Liu, F. (2016) · Journal of Cancer · doi:10.7150/jca.14549 · Cited by 159
Woensel, M. V., Mathivet, T., Wauthoz, N., Rosière, R., Garg, A. D., Agostinis, P., Mathieu, V., Robert Kiss, A., Lefranc, F., Boon, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01279-1 · Cited by 152
Kondo, Y., Ohno, T., Nishii, N., Harada, K., Yagita∥, H., & Azuma, M. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.04.005 · Cited by 142
Trowbridge, J. J., Sinha, A. U., Zhu, N., Li, M., Armstrong, S. A., & Orkin, S. H. (2012) · Genes & Development · doi:10.1101/gad.184341.111 · Cited by 137 · cited 1×
“Knocking out Dmnt-1 shut down leukemogenesis and leukemic stem cell renewal without affecting normal hematopoiesis [27].”
BackgroundDave, B., Granados-Principal, S. M., Zhu, R., Benz, S. C., Rabizadeh, S., Soon‐Shiong, P., Yu, K., Shao, Z., Li, X., Gilcrease, M. Z., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320769111 · Cited by 122
Cancer Immunotherapy, Part 1: Current Strategies and Agents.
Ventola, C. L. (2017) · PubMed · Cited by 120
Marra, M., Salzano, G., Leonetti, C., Tassone, P., Scarsella, M., Zappavigna, S., Calimeri, T., Franco, R., Liguori, G., Cigliana, G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.03.004 · Cited by 109
Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery
Shen, H., Rodriguez‐Aguayo, C., Xu, R., González-Villasana, V., Mai, J., Huang, Y., Zhang, G., Guo, X., Bai, L., Qin, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2764 · Cited by 108
Rodríguez, J. A. (2017) · Oncology Letters · doi:10.3892/ol.2017.6784 · Cited by 101
Marra, M., Salzano, G., Leonetti, C., Porru, M., Franco, R., Zappavigna, S., Liguori, G., Botti, G., Chieffi, P., Lamberti, M., et al. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.06.018 · Cited by 95
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
Salzano, G., Marra, M., Porru, M., Zappavigna, S., Abbruzzese, A., Rotonda, M. I. L., Leonetti, C., Caraglia, M., & Rosa, G. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.10.046 · Cited by 89
CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy
Yao, S., He, Z., & Chen, C. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.067 · Cited by 72
Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk
Seidel, D., Azcárate-Peril, M. A., Chapkin, R. S., & Turner, N. D. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.009 · Cited by 69
Zoledronic acid: an unending tale for an antiresorptive agent
Caraglia, M., Marra, M., Naviglio, S., Botti, G., Addeo, R., & Abbruzzese, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903485664 · Cited by 57
Gut microbiota sways response to cancer immunotherapy
York, A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2018.12 · Cited by 57
Immunotherapy Approaches in Cancer Treatment
Klener, P., Otáhal, P., Latečková, L., & Klener, P. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150619114554 · Cited by 53
Kopecka, J., Porto, S., Lusa, S., Gazzano, E., Salzano, G., Pinzón‐Daza, M. L., Giordano, A., Desiderio, V., Ghigo, D., Rosa, G. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8012 · Cited by 52
New approaches for cancer immunotherapy
Karlıtepe, A., Özalp, Ö., & Avcı, Ç. B. (2015) · Tumor Biology · doi:10.1007/s13277-015-3491-2 · Cited by 43
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Ferrari, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Prebiotics: A Potential Treatment Strategy for the Chemotherapy-damaged Gut?
Wang, H., Geier, M. S., & Howarth, G. S. (2014) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2012.741082 · Cited by 35
Cancer immunology for the clinician.
Weiner, L. M. (2015) · PubMed · Cited by 33
Schiraldi, C., Zappavigna, S., Agostino, A. D., Porto, S., Gaito, O., Lusa, S., Lamberti, M., ROSA, M. D., Rosa, G. D., & Caraglia, M. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.955989 · Cited by 17
Mu, C., Wu, X., Ma, H., Tao, W., Zhang, G., Xia, X., Shen, J., Mai, J., Sun, T., Sun, X., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0577-t · Cited by 6
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
“In addition, the PD‐1 receptor is also found on T cells, where, upon binding to the ligand PD‐L1, induces a conformational change to an inactive and dysfunctional state [35].”
BackgroundGenome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
Metadata
- Authors
- Sambi, M., Bagheri, L., & Szewczuk, M. R.
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2019-02-28
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- OpenAlex
- W2918589641
- Cited by
- 313
- References
- 60
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.